Purpose: To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints in healthy young individuals. Participants: 20 healthy males and females aged 18-35 years. Procedures (methods): Subjects will be randomly exposed to three consecutive days of filtered air (4 hr/day) and three consecutive days of PM2.5 (approximately 35 µg/m3; 4 hr/day) in an exposure chamber. Blood collection for inflammatory factors such as C-reactive protein (CRP), clotting factors; heart rate variability (HRV); spirometry; and a symptom questionnaire will be conducted before and after each exposure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
20
To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.
To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
EPA Human Studies Facility
Chapel Hill, North Carolina, United States
RECRUITINGBlood inflammation marker, CRP, will be measured 2 hours before each air exposure day and follow up day in 20 subjects
Venous blood will be collected for CRP measurement 2 hours before each air exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.
Time frame: Four days
Blood inflammation marker, CRP, will be measured 2 hours before each PM exposure day and follow up day in 20 subjects
Venous blood will be collected for CRP measurement 2 hours before each PM exposure day on day 1, day 2, day 3 and follow up day in 20 subjects.
Time frame: Four days
Blood inflammation marker, CRP, will be measured 1 hour after each air exposure day in 20 subjects
Venous blood will be collected for CRP measurement 1 hour after each air exposure day on day 1, day 2, and day 3 in 20 subjects.
Time frame: Three days
Blood inflammation marker, CRP, will be measured 1 hour after each PM exposure day in 20 subjects
Venous blood will be collected for CRP measurement 1 hour after each PM exposure day on day 1, day 2, and day 3 in 20 subjects.
Time frame: Three days
Spirometry will be measured 1 hour before each air exposure day and follow up day in 20 subjects
FEV1 and FVC will be measured by spirometry 1 hour before each air exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.
Time frame: Four days
Spirometry will be measured 1 hour before each PM exposure day and follow up day in 20 subjects
FEV1 and FVC will be measured by spirometry 1 hour before each PM exposure day on day 1, day 2, day 3 and follow up day in 20 subjects.
Time frame: Four days
Ambulatory ECG will be measured 2 hours before each air exposure day and follow up day in 20 subjects
ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hour before each air exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.
Time frame: Four days
Ambulatory ECG will be measured 2 hours before each PM exposure day and follow up day in 20 subjects
ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hours before each PM exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.
Time frame: Four days
Spirometry will be measured 1 hour after each air exposure day in 20 subjects
FEV1 and FVC will be measured by spirometry 1 hour after each air exposure day on day 1, day 2, and day 3 in 20 subjects.
Time frame: Three days
Spirometry will be measured 1 hour after each PM exposure day in 20 subjects
FEV1 and FVC will be measured by spirometry 1 hour after each PM exposure day on day 1, day 2, and day 3 in 20 subjects.
Time frame: Three days
Ambulatory ECG will be measured 2 hours after each air exposure day in 20 subjects
ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hours after each air exposure day on day 1, day 2, and day 3 in 20 subjects.
Time frame: Three days
Ambulatory ECG will be measured 2 hours after each PM exposure day in 20 subjects
ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hours after each PM exposure day on day 1, day 2, and day 3 in 20 subjects.
Time frame: Three days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.